T Schalekamp

Summary

Affiliation: Utrecht University
Country: The Netherlands

Publications

  1. ncbi request reprint Acenocoumarol stabilization is delayed in CYP2C93 carriers
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 75:394-402. 2004
  2. doi request reprint Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins
    Tom Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Arch Intern Med 168:180-5. 2008
  3. pmc Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction
    Tom Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Eur J Clin Pharmacol 63:335-43. 2007
  4. ncbi request reprint VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement
    T Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 81:185-93. 2007
  5. ncbi request reprint Discrepancies between medication records of anticoagulation clinics and pharmacy records
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 15:823-8. 2006
  6. ncbi request reprint VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 80:13-22. 2006
  7. ncbi request reprint CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 79:511-20. 2006
  8. doi request reprint An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol
    R M F Van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    J Thromb Haemost 10:767-72. 2012
  9. doi request reprint Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
    T I Verhoef
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciuences, Utrecht University, Utrecht, The Netherlands
    J Thromb Haemost 10:606-14. 2012
  10. pmc Suboptimal choices and dosing of statins at start of therapy
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 60:83-9. 2005

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Acenocoumarol stabilization is delayed in CYP2C93 carriers
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 75:394-402. 2004
    ..Our objective was to assess whether there is an association between the presence of allelic variants of the gene for cytochrome P450 (CYP) 2C9 and anticoagulation problems during the initial 3 to 6 months of acenocoumarol treatment...
  2. doi request reprint Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins
    Tom Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Arch Intern Med 168:180-5. 2008
    ....
  3. pmc Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction
    Tom Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Eur J Clin Pharmacol 63:335-43. 2007
    ....
  4. ncbi request reprint VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement
    T Schalekamp
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 81:185-93. 2007
    ..A combination of polymorphisms of both genotypes is associated with a strongly increased risk of overanticoagulation, whereas delayed stabilization is mainly associated with the CYP2C9 genotype...
  5. ncbi request reprint Discrepancies between medication records of anticoagulation clinics and pharmacy records
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 15:823-8. 2006
    ....
  6. ncbi request reprint VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 80:13-22. 2006
    ..Our objective was to assess the effects of VKORC1 and CYP2C9 genotypes on severe overanticoagulation and time to achieve stability and their contributions to dose requirement during the initial phase of acenocoumarol treatment...
  7. ncbi request reprint CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Pharmacol Ther 79:511-20. 2006
  8. doi request reprint An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol
    R M F Van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    J Thromb Haemost 10:767-72. 2012
    ..Previous studies have provided contradictory results regarding the interaction between the CYP2C9 and VKORC1 genotypes affecting various outcome measures...
  9. doi request reprint Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
    T I Verhoef
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciuences, Utrecht University, Utrecht, The Netherlands
    J Thromb Haemost 10:606-14. 2012
    ..The required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes. However, the duration of the effects of these genes on anticoagulation is not yet known...
  10. pmc Suboptimal choices and dosing of statins at start of therapy
    Aukje K Mantel-Teeuwisse
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Br J Clin Pharmacol 60:83-9. 2005
    ..To assess dosing and determinants of the choice of statins among starters of statins...
  11. ncbi request reprint Compliance with national guidelines for the management of drug-drug interactions in Dutch community pharmacies
    Henk Buurma
    SIR Institute for Pharmacy Practice and Policy, Leiden, The Netherlands
    Ann Pharmacother 41:2024-31. 2007
    ..Little is known about compliance with pharmacy practice guidelines for the management of drug-drug interaction alerts...
  12. ncbi request reprint Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status
    Tom Schalekamp
    Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht
    Clin Pharmacol Ther 76:409-17. 2004
    ..Our objective was to assess whether there is an association between the presence of allelic variants of the gene for cytochrome P450 (CYP) 2C9 and anticoagulation problems during the initial phase of phenprocoumon treatment...
  13. ncbi request reprint Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?
    Tom Schalekamp
    Thromb Haemost 100:175-6. 2008
  14. ncbi request reprint Potential determinants of drug-drug interaction associated dispensing in community pharmacies
    Matthijs L Becker
    National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Drug Saf 28:371-8. 2005
    ..Further assessment of the relation between these determinants and the dispensing of DDIs and of the relation between DDI-associated dispensing and patient harm is recommended...